Related Experiment Video
Updated: Sep 14, 2025

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
Economic evaluation of hypertension screening in Iran using a Markov model
Rajabali Daroudi1, Ali Akbari Sari1, Mahmoud Zamandi1
1Department of Health Management, policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Insights
Regular blood pressure screening is more cost-effective than no screening for preventing cardiovascular disease. Screening every two years from age 30 offers the best value, considering economic thresholds.
Area of Science:
- Public Health
- Health Economics
- Cardiovascular Disease Prevention
Background:
- Hypertension is a leading global non-communicable disease, significantly increasing cardiovascular disease (CVD) risks like coronary heart disease and stroke.
- Effective screening strategies are crucial for early detection and management of hypertension to mitigate severe health outcomes.
Purpose of the Study:
- To conduct a comprehensive economic evaluation of various high blood pressure screening strategies in Iran for the year 2020.
- To identify the most cost-effective approach for hypertension screening within the Iranian healthcare context.
Main Methods:
- Utilized a Markov model to assess nine distinct blood pressure screening strategies (varying frequency and starting age).
- Estimated quality-adjusted life years (QALYs) and costs from a societal perspective over a lifetime horizon.
- Input data sourced from literature, expert opinions, and existing datasets for model calibration.
Main Results:
- All evaluated screening strategies demonstrated higher cost-effectiveness than no screening.
- Five strategies, including triennial screening from ages 30, 40, 50, and biennial/annual screening from age 30, were found to be undominated.
- Biennial or triennial screening from age 30 emerged as the most cost-effective at a threshold near one times GDP per capita.
Conclusions:
- All hypertension screening strategies are economically favorable compared to passive surveillance.
- A screening strategy involving checks every two years, commencing at age 30, is identified as the most cost-effective option in Iran, particularly when considering a cost-effectiveness threshold of one times GDP per capita.
Introduction And Purpose:
Hypertension is one of the most common non-communicable diseases in the world and plays a significant role in the occurrence of cardiovascular complications, including coronary heart disease (CHD) and strokes. Therefore, the purpose of this study is to conduct an economic evaluation of high blood pressure screening strategies in Iran in 2020.
Method:
We did an economic evaluation of 9 blood pressure screening strategies, including screening annually or every two or three years from the ages of 30, 40, or 50, using the Markov model. The Markov model was designed and implemented based on the natural history of cardiovascular disease in the 2020 TreeAge Pro software. The quality-adjusted life years and the average cost of high blood pressure screening and treatment per person were estimated from society's perspective for the lifetime. Input data of the model were derived from published literature, expert opinion, and available data sources.
Findings:
All screening interventions were more costly and more effective compared to no screening. Five strategies, including screening every three years from the age of 50, 40, and 30 years and screening every two years and annually from the age of 30, were undominated. Incremental cost-effectiveness ratios for these strategies ranged from $PPP 2,675.20 to 20,466.83. Probabilistic sensitivity analysis indicated that, at a cost-effectiveness threshold close to one times the GDP per capita, screening every two or three years from age 30 had the highest cost-effectiveness, with probabilities of 0.522 and 0.44, respectively.
Conclusion:
Based on the findings of the economic evaluation, all screening strategies are more cost-effective compared to no screening, and among the screening strategies, considering about one times the GDP per capita as the cost-effectiveness threshold, a screening strategy every two years, starting at the age of 30, is the most cost-effective strategy.
More Related Videos
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Errors occurring during blood pressure monitoring
Several factors...
Hypertension I: Introduction
Pre-Procedural Guidelines for Assessing Blood Pressure
Hypertension V: Nursing Management
Hypertension and Regulation of Blood Pressure

